Sarcomatrix
Clinical-stage biotechnology company developing therapies for muscle-wasting diseases. The company focuses on small-molecule integrin activators and recombinant laminin protein replacement to enhance muscle regeneration, and operates a proprietary functional screening platform to advance candidates from discovery through IND-enabling studies and early clinical trials.
Industries
Nr. of Employees
small (1-50)
Sarcomatrix
San Francisco, California, United States, North America
Products
S-969
Oral small-molecule therapeutic candidate designed to enhance muscle regeneration by modulating integrin-related pathways and the Hippo‑YAP axis; advanced through preclinical development including large-animal studies and IND-enabling activities.
Recombinant laminin-111 (rhLAM-111)
Protein replacement therapy candidate intended to substitute for defective laminin in LAMA2-related dystrophies; under preclinical development and holding orphan drug designation in the EU.
lead oral small molecule therapy
Sarcomatrix's lead oral small molecule therapy is aimed at treating muscle-wasting diseases such as Duchenne muscular dystrophy (DMD), sarcopenia, and cachexia by targeting underlying mechanisms of muscle degeneration to preserve and restore muscle function across diverse patient populations.
Protein replacement therapy using laminin-111
A potential treatment for LAMA2-related muscular dystrophy, Duchenne muscular dystrophy, and other muscular dystrophies, promoting muscle repair and regeneration.
recombinant human laminin-111 (rhLAM-111)
A potential therapy for LAMA2-related muscular dystrophy (LAMA2-RD) and Duchenne Muscular Dystrophy (DMD), showing promise in preclinical studies to support muscle integrity and function.
Small molecule α7β1 integrin activators
Small molecule activators that stimulate muscle regeneration in mouse models and may support treatment of various muscular dystrophies including Duchenne, Becker, Emery-Dreifuss, Facioscapulohumeral, Limb-Girdle, and Congenital muscular dystrophy.
S-969
Oral small-molecule therapeutic candidate designed to enhance muscle regeneration by modulating integrin-related pathways and the Hippo‑YAP axis; advanced through preclinical development including large-animal studies and IND-enabling activities.
Recombinant laminin-111 (rhLAM-111)
Protein replacement therapy candidate intended to substitute for defective laminin in LAMA2-related dystrophies; under preclinical development and holding orphan drug designation in the EU.
lead oral small molecule therapy
Sarcomatrix's lead oral small molecule therapy is aimed at treating muscle-wasting diseases such as Duchenne muscular dystrophy (DMD), sarcopenia, and cachexia by targeting underlying mechanisms of muscle degeneration to preserve and restore muscle function across diverse patient populations.
Protein replacement therapy using laminin-111
A potential treatment for LAMA2-related muscular dystrophy, Duchenne muscular dystrophy, and other muscular dystrophies, promoting muscle repair and regeneration.
recombinant human laminin-111 (rhLAM-111)
A potential therapy for LAMA2-related muscular dystrophy (LAMA2-RD) and Duchenne Muscular Dystrophy (DMD), showing promise in preclinical studies to support muscle integrity and function.
Small molecule α7β1 integrin activators
Small molecule activators that stimulate muscle regeneration in mouse models and may support treatment of various muscular dystrophies including Duchenne, Becker, Emery-Dreifuss, Facioscapulohumeral, Limb-Girdle, and Congenital muscular dystrophy.
Services
Functional, high-throughput screening and lead identification service focused on phenotypic improvements in muscle cell function and regeneration; delivered via collaborative research and in-house discovery programs.
Functional, high-throughput screening and lead identification service focused on phenotypic improvements in muscle cell function and regeneration; delivered via collaborative research and in-house discovery programs.
Expertise Areas
- Small-molecule drug discovery for muscle disease
- Protein replacement therapy development
- Translational and preclinical muscle biology
- IND-enabling development and regulatory strategy
Key Technologies
- Integrin modulation (α7β1)
- Recombinant laminin-111 protein therapeutics
- Small-molecule targeting of Hippo‑YAP signaling
- Functional high-throughput screening
News & Updates
Company presentations and pitches at multiple JPM Week partnering events in San Francisco, highlighting lead programs and partnership opportunities.
Opinion piece discussing the role of small molecules in muscular dystrophy treatment relative to gene therapy approaches.
Announcement of a $300,000 investment to accelerate development of next-generation treatments for Duchenne muscular dystrophy.
Sarcomatrix Therapeutics Launches Regulation D Offering to Advance Novel Oral Muscle Disease Therapy
Regulation D private placement announcement to fund IND-enabling studies and first-in-human trials for the lead oral small molecule program.
Renewal of orphan drug designation in the EU for recombinant laminin-111 and expansion of preclinical research into Duchenne muscular dystrophy.
Announcement that the lead small-molecule candidate advanced to large-animal efficacy and safety studies as part of IND-enabling development.
Company presentations and pitches at multiple JPM Week partnering events in San Francisco, highlighting lead programs and partnership opportunities.
Opinion piece discussing the role of small molecules in muscular dystrophy treatment relative to gene therapy approaches.
Announcement of a $300,000 investment to accelerate development of next-generation treatments for Duchenne muscular dystrophy.
Sarcomatrix Therapeutics Launches Regulation D Offering to Advance Novel Oral Muscle Disease Therapy
Regulation D private placement announcement to fund IND-enabling studies and first-in-human trials for the lead oral small molecule program.
Renewal of orphan drug designation in the EU for recombinant laminin-111 and expansion of preclinical research into Duchenne muscular dystrophy.
Announcement that the lead small-molecule candidate advanced to large-animal efficacy and safety studies as part of IND-enabling development.